Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase

Molecular Endocrinology

Volumn 18, Issue 1, 2004, Pages 162-172

  Facchetti, Marco ^a   Uberti, Daniela ^a   Memo, Maurizio ^a   Missale, Cristina ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; WORTMANNIN;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOPHYSIS TUMOR; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BASE SEQUENCE; BROMOCRIPTINE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; MICE; NERVE GROWTH FACTOR; PITUITARY NEOPLASMS; PROLACTINOMA; PROTEIN CONFORMATION; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0347286635     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0190     Document Type: Article

References (55)

1. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, Balsari A, Spano PF 1993 Nerve growth factor suppressed the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90:5781-5785
2. Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano PF 1996 Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol 10:272-285
3. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF 1995 Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J Cancer 72:1397-1399
4. Chao MV, Hempstead BL 1995 p75 and trk: a two receptor system. Trends Neurosci 18:321-326
5. Kaplan DR, Stephens RM 1994 Neurotrophin signal transduction by the trk receptor. J Neurobiol 25:1404-1417
6. Soltoff SP, Rabin SL, Cantley LC, Kaplan DR 1992 Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. J Biol Chem 267:17472-17477
7. Choi DY, Toledo-Aral JJ, Segal R, Halegoua S 2001 Sustained signalling by phospholipase C-γ mediates nerve growth factor-triggered gene expression. Mol Cell Biol 21:2695-2705
8. Carter BD, Lewin GR 1997 Neurotrophins live or let die: does p75 decide? Neuron 18:187-190
9. NGFR-mediated activation of nuclear factor-κB. Mol Endocrinol 16:353-366
10. Descamps S, Toillon RA, Adriaenssens E, Pawlowski W, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP, Hondermarck H 2001 Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signalling pathways. J Biol Chem 276:17864-17870
11. Sortino MA, Condorelli F, Vancheri C, Chiarenza A, Bernardini R, Consoli U, Canonico PL 2000 Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. Mol Endocrinol 14:124-136
12. Hughes AL, Gollapudi L, Sladek TL, Neet KE 2000 Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. J Biol Chem 275:37829-37837
13. Cip/WAF1 in NIH-3T3 cells expressing TrkA. J Biol Chem 270:30841-30844
14. Matsushima H, Bogenmann E 1993 Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol 13:7447-7456
15. Krygier S, Djakiew D 2002 Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98:1-7
16. Khwaja F, Djakiew D 2003 Inhbition of cell cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor. Mol Carcinog 36:153-160
17. Weis C, Wiesenhofer B, Humpel C 2002 Nerve growth factor plays a divergent role in mediating growth of rat C6 glioma cells via binding to the p75 neurotrophin receptor. J Neurooncol 56:59-67
18. Johnson DG, Walker CL 1999 Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295-312
19. Bullock AN, Fresht AR 2001 Rescuing the function of mutant p53. Nat Rev Cancer 1:68-76
20. Webley KM, Shorthouse AJ, Royds JA 2000 Effect of mutation and conformation on the function of p53 in colorectal cancer. J Pathol 191:361-367
21. Gaitonde SV, Riley JR, Qiao D, Martinez JD 2000 Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 19:4042-4049
22. Moll UM, Riou G, Levine AJ 1992 Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266
23. Moll UM, Ostermeyer AG, Haladay AG, Windfield B, Frazier M, Zambetti 1996 Cytoplasmic sequestration of wild type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16:1126-1137
24. Schlamp CL, Poulsen GL, Nork TM, Nickells RW 1997 Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J Natl Cancer Inst 89:1530-1536
25. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Fatelson MA, Jay G 1995 Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41-47
26. Nikolaev AY, Li M, Puskas N, Qin J, Gu W 2003 Parc: a cytoplasmic anchor for p53. Cell 112:20-40
27. Herman V, Drazin NZ, Gonsky R, Melmed S 1993 Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77:50-55
28. Levy A, Hall L, Yendall WA, Lightman SL 1994 p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 41:809-814
29. Pei L, Melmed S, Scheithauer BW, Kovacs K, Prager D 1994 H-ras mutations in human pituitary carcinoma metastasis. J Clin Endocrinol Metab 78:842-846
30. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M 1996 p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16:5178-5185
31. Gollapudi L, Neet KE 1997 Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine. J Neurosci Res 49:461-474
32. Meplan C, Richard MJ, Hainaut P 2000 Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol 59:25-33
33. Vemaegh GW, Richard MJ, Hainaut P 1997 Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol Cell Biol 17:5699-5706
34. Meplan C, Richard MJ, Hainaut P 2000 Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19:5227-5236
35. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689
36. Woscholski R, Kodaki T, Mc Kinnon M, Waterfield MD, Parker PS 1994 A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase. FEBS Lett 342:109-114
37. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489-501
38. Brown JP, Pagano M 1997 Mechanism of p53 degradation. Biochim Biophys Acta 1332:O1-O6
39. Haupt Y, Maya R, Kazaz A, Oren M 1997 Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
40. Fontoura BM, Atienza CA, Sorokina EA, Moromoto T, Carroll RB 1997 Cytoplasmic p53 polypeptide is associated with ribosomes. Mol Cell Biol 17:3146-3154
41. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T 2000 p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2:709-717
42. Klotzsche O, Etzrodt D, Hohenberg H, Bohn W, Deppert W 1998 Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament (vimentin) scaffold. Oncogene 16:3423-3434
43. Metcalfe S, Weeds A, Okorokov AL, Milner J, Cockman M, Pope B 1999 Wild-type p53 protein shows calcium-dependent binding to F-actin. Oncogene 18:2351-2355
44. Thapar K, Scheithauer BW, Kovacs K, Pemicone P, Laws ER 1996 P53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765-771
45. Green VL, White MC, Hipkin LJ, Jeffreys TV, Foy PM, Atkin SL 1997 Apoptosis and p53 tumor suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol 136:382-387
46. Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH 2001 Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54: 317-325
47. Milner J 1995 Flexibility: the key to p53 function? Trends Biochem Sci 20:49-51
48. Moll UM, LaQuaglia M, Bernard M, Riou G 1995 Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411
49. Isaacs JS, Hardman R, Carman TA, Barret JC, Weissman BE 1998 Differential subcellular p53 localization and function in N-and S-type neuroblastoma cell lines. Cell Growth Differ 9:545-555
50. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AKC 1995 p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147:790-798
51. Weiss J, Heine M, Corner B, Pilch H, Jung EG 1995 Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 133:23-31
52. Deleted in proof
53. WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60:5390-5394
54. Fukuchi K, Watanabe H, Tomoyasu S, Ichimura S, Tatsumi K, Gomi K 2000 Phosphatidylinositol 3-kinase inhibitors, wortmannin or LY294002, inhibited accumulation of p21 protein after γ-irradiation by stabilization of the protein. Biochim Biophys Acta 1496:207-220
55. Okaichi K, Suzuki K, Morita N, Ikeda M, Takhashi H, Matsuda N, Watanabe M, Okumura Y 2002 Low dose of wortmannin reduces radiosensitivity of human glioblastoma cells through the p53 pathway. Oncol Rep 9:859-862